Vista Investment Partners LLC Takes $3.47 Million Position in Hinge Health Inc. $HNGE

Vista Investment Partners LLC acquired a new stake in shares of Hinge Health Inc. (NYSE:HNGE) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 41,789 shares of the company’s stock, valued at approximately $3,468,000. Vista Investment Partners LLC owned 0.05% of Hinge Health as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the stock. BNP Paribas Financial Markets increased its holdings in shares of Hinge Health by 162.7% in the 4th quarter. BNP Paribas Financial Markets now owns 727,672 shares of the company’s stock valued at $33,800,000 after acquiring an additional 450,643 shares during the period. UBS Group AG lifted its stake in shares of Hinge Health by 168.8% during the 4th quarter. UBS Group AG now owns 356,701 shares of the company’s stock worth $16,569,000 after purchasing an additional 223,980 shares during the last quarter. Royce & Associates LP purchased a new stake in shares of Hinge Health during the 4th quarter worth $2,091,000. Alkeon Capital Management LLC boosted its position in Hinge Health by 110.4% during the fourth quarter. Alkeon Capital Management LLC now owns 791,104 shares of the company’s stock valued at $36,747,000 after purchasing an additional 415,093 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Hinge Health by 755.1% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 27,354 shares of the company’s stock valued at $1,271,000 after purchasing an additional 24,155 shares during the last quarter.

Insiders Place Their Bets

In other Hinge Health news, President James Pursley sold 33,000 shares of the business’s stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $69.31, for a total transaction of $2,287,230.00. Following the sale, the president owned 740,897 shares in the company, valued at approximately $51,351,571.07. The trade was a 4.26% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, major shareholder Insight Holdings Group, Llc sold 181,499 shares of the stock in a transaction dated Thursday, July 9th. The shares were sold at an average price of $90.20, for a total value of $16,371,209.80. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 3,715,194 shares of company stock valued at $287,886,932. 18.92% of the stock is owned by company insiders.

Hinge Health Trading Down 0.3%

Shares of Hinge Health stock opened at $89.04 on Monday. The firm’s 50 day simple moving average is $76.22 and its two-hundred day simple moving average is $55.01. The firm has a market capitalization of $6.89 billion, a price-to-earnings ratio of 69.56 and a beta of 1.31. Hinge Health Inc. has a 12-month low of $30.08 and a 12-month high of $91.50.

Hinge Health (NYSE:HNGE) last posted its quarterly earnings data on Tuesday, August 4th. The company reported $0.59 EPS for the quarter, topping the consensus estimate of $0.28 by $0.31. The business had revenue of $212.82 million during the quarter. Hinge Health had a net margin of 15.15% and a return on equity of 65.44%. The company’s quarterly revenue was up 53.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.59 earnings per share. On average, sell-side analysts predict that Hinge Health Inc. will post 1.37 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have commented on HNGE shares. Piper Sandler reissued an “overweight” rating on shares of Hinge Health in a research report on Wednesday, June 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Hinge Health in a research report on Monday, August 3rd. Wall Street Zen lowered shares of Hinge Health from a “buy” rating to a “hold” rating in a research note on Saturday. Evercore reissued an “outperform” rating and set a $105.00 target price on shares of Hinge Health in a research report on Wednesday. Finally, Morgan Stanley raised their target price on shares of Hinge Health from $72.00 to $108.00 and gave the company an “overweight” rating in a research note on Monday, July 13th. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Hinge Health currently has an average rating of “Moderate Buy” and a consensus price target of $98.64.

Hinge Health Company Profile

Hinge Health (NYSE: HNGE) is a digital musculoskeletal (MSK) clinic that provides end-to-end solutions for the prevention and management of musculoskeletal conditions. The company’s platform combines wearable motion sensors, personalized exercise therapy guided by licensed physical therapists, and behavioral health coaching to deliver tailored treatment plans. By integrating technology with evidence-based clinical protocols, Hinge Health aims to reduce pain, improve mobility and decrease reliance on more invasive interventions such as surgery or opioid prescriptions.

Founded in 2015 and headquartered in San Francisco, Hinge Health partners with employers, health plans and other payers to offer its self-directed, app-based programs.